Foundation for Biomedical Research and Innovation TR1308, Kobe, Japan.
Tissue Eng Part A. 2010 Nov;16(11):3329-41. doi: 10.1089/ten.TEA.2009.0739. Epub 2010 Jul 23.
Expression of the Wnt modulator secreted frizzled related protein 4 (Sfrp4) is upregulated after heart ischemic injury. We show that intramuscular administration of recombinant Sfrp4 to rat heart ischemic injury and recanalization models prevents further deterioration of cardiac function after the ischemic injury. The effect of Sfrp4 persisted for at least 20 weeks when Sfrp4 was administered in a slow release system (Sfrp4-polyhedra) to both acute and subacute ischemic models. The histology of the dissected heart showed that the cardiac wall was thicker and the area of acellular scarring was smaller in Sfrp4-treated hearts than in controls. Increased amounts of both the inactive serine 9-phosphorylated form of glycogen synthase kinase (GSK)-3β and the active form of β-catenin were observed by immunohistology 3 days after lateral anterior descendant ligation in control, but not in Sfrp4-treated hearts. All together, we show that administration of Sfrp4 interferes with canonical Wnt signaling that could mediate the formation of acellular scar and consequently contributes to the prevention of aggravation of cardiac function.
Wnt 调节剂分泌型卷曲相关蛋白 4(Sfrp4)的表达在心脏缺血性损伤后上调。我们表明,将重组 Sfrp4 肌肉内给药于大鼠心脏缺血再灌注模型可防止缺血性损伤后心脏功能进一步恶化。当 Sfrp4 在急性和亚急性缺血模型中以缓慢释放系统(Sfrp4-多面体)给药时,Sfrp4 的作用至少持续 20 周。解剖心脏的组织学显示,在 Sfrp4 处理的心脏中,心肌壁较厚,无细胞瘢痕面积较小。免疫组化显示,在对照心脏中,外侧前降支结扎后 3 天可观察到糖原合酶激酶(GSK)-3β的无活性丝氨酸 9 磷酸化形式和β-连环蛋白的活性形式的含量增加,但在 Sfrp4 处理的心脏中则没有。总之,我们表明,Sfrp4 的给药会干扰经典的 Wnt 信号通路,该通路可能介导无细胞瘢痕的形成,从而有助于防止心脏功能恶化。